|
1
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepherd JE: Current strategies for
prevention, detection, and treatment of ovarian cancer. J Am Pharm
Assoc (Wash). 40:392–401. 2000.PubMed/NCBI
|
|
3
|
Agarwal R and Kaye SB: Ovarian cancer:
strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brabec V and Kasparkova J: Modifications
of DNA by platinum complexes. Relation to resistance of tumors to
platinum antitumor drugs. Drug Resist Updat. 8:131–146. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
White KL, Rider DN, Kalli KR, Knutson KL,
Jarvik GP and Goode EL: Genomics of the NF-κB signaling pathway:
hypothesized role in ovarian cancer. Cancer Causes Control.
22:785–801. 2011.
|
|
7
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
9
|
Baud V and Karin M: Is NF-kappaB a good
target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov.
8:33–40. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK
and Cheng AL: Increase of the resistance of human cervical
carcinoma cells to cisplatin by inhibition of the MEK to ERK
signaling pathway partly via enhancement of anticancer drug-induced
NF kappa B activation. Biochem Pharmacol. 63:1423–1430. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen BJ: Triptolide, a novel
immunosuppressive and anti-inflammatory agent purified from a
Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma.
42:253–265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen YW, Lin GJ, Chia WT, Lin CK, Chuang
YP and Sytwu HK: Triptolide exerts anti-tumor effect on oral cancer
and KB cells in vitro and in vivo. Oral Oncol. 45:562–568. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu W, Hu H, Qiu P and Yan G: Triptolide
induces apoptosis in human anaplastic thyroid carcinoma cells by a
p53-independent but NF-kappaB-related mechanism. Oncol Rep.
22:1397–1401. 2009.PubMed/NCBI
|
|
14
|
Li H, Takai N, Yuge A, et al: Novel target
genes responsive to the anti-growth activity of triptolide in
endometrial and ovarian cancer cells. Cancer Lett. 297:198–206.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim MJ, Lee TH, Kim SH, Choi YJ, Heo J and
Kim YH: Triptolide inactivates Akt and induces caspase-dependent
death in cervical cancer cells via the mitochondrial pathway. Int J
Oncol. 37:1177–1185. 2010.PubMed/NCBI
|
|
16
|
Wu PP, Liu KC, Huang WW, et al: Triptolide
induces apoptosis in human adrenal cancer NCI-H295 cells through a
mitochondrial-dependent pathway. Oncol Rep. 25:551–557.
2011.PubMed/NCBI
|
|
17
|
Antonoff MB, Chugh R, Borja-Cacho D, et
al: Triptolide therapy for neuroblastoma decreases cell viability
in vitro and inhibits tumor growth in vivo. Surgery. 146:282–290.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee KY, Park JS, Jee YK and Rosen GD:
Triptolide sensitizes lung cancer cells to TNF-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition
of NF-kappaB activation. Exp Mol Med. 34:462–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morgan MJ and Liu ZG: Crosstalk of
reactive oxygen species and NF-kappaB signaling. Cell Res.
21:103–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kane DJ, Sarafian TA, Anton R, et al:
Bcl-2 inhibition of neural death: decreased generation of reactive
oxygen species. Science. 262:1274–1277. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu GH, Wang SR, Wang B and Kong BH:
Inhibition of nuclear factor-kappaB by an antioxidant enhances
paclitaxel sensitivity in ovarian carcinoma cell line. Int J
Gynecol Cancer. 16:1777–1782. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cohen GM: Caspases: the executioners of
apoptosis. Biochem J. 326:1–16. 1997.
|
|
23
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang J, Nakamura H and Iyer AK:
Tumor-targeted induction of oxystress for cancer therapy. J Drug
Target. 15:475–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adam-Vizi V and Chinopoulos C:
Bioenergetics and the formation of mitochondrial reactive oxygen
species. Trends Pharmacol Sci. 27:639–645. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Silasi DA, Alvero AB, Rutherford TJ, Brown
D and Mor G: Phenoxodiol: pharmacology and clinical experience in
cancer monotherapy and in combination with chemotherapeutic drugs.
Expert Opin Pharmacother. 10:1059–1067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sung B, Kunnumakkara AB, Sethi G, Anand P,
Guha S and Aggarwal BB: Curcumin circumvents chemoresistance in
vitro and potentiates the effect of thalidomide and bortezomib
against human multiple myeloma in nude mice model. Mol Cancer Ther.
8:959–970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang YI, Kim JH, Lee KT and Choi JH:
Costunolide induces apoptosis in platinum-resistant human ovarian
cancer cells by generating reactive oxygen species. Gynecol Oncol.
123:588–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berkenblit A and Cannistra SA: Advances in
the management of epithelial ovarian cancer. J Reprod Med.
50:426–438. 2005.
|
|
30
|
Yang M, Huang J, Pan HZ and Jin J:
Triptolide overcomes dexamethasone resistance and enhanced
PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human
multiple myeloma cells. Int J Mol Med. 22:489–496. 2008.PubMed/NCBI
|
|
31
|
Chen YW, Lin GJ, Chuang YP, et al:
Triptolide circumvents drug-resistant effect and enhances
5-fluorouracil antitumor effect on KB cells. Anticancer Drugs.
21:502–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hampton MB and Orrenius S: Redox
regulation of apoptotic cell death. Biofactors. 8:1–5. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toyokuni S, Okamoto K, Yodoi J and Hiai H:
Persistent oxidative stress in cancer. FEBS Lett. 358:1–3. 1995.
View Article : Google Scholar
|
|
34
|
Fruehauf JP and Meyskens FL Jr: Reactive
oxygen species: a breath of life or death? Clin Cancer Res.
13:789–794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maiti AK: Genetic determinants of
oxidative stress-mediated sensitization of drug-resistant cancer
cells. Int J Cancer. 130:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kurosu T, Fukuda T, Miki T and Miura O:
BCL6 overexpression prevents increase in reactive oxygen species
and inhibits apoptosis induced by chemotherapeutic reagents in
B-cell lymphoma cells. Oncogene. 22:4459–4468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maiti AK: Gene network analysis of
oxidative stress-mediated drug sensitivity in resistant ovarian
carcinoma cells. Pharmacogenomics J. 10:94–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu B, Guo X, Mathew S, et al: Triptolide
simultaneously induces reactive oxygen species, inhibits NF-kappaB
activity and sensitizes 5-fluorouracil in colorectal cancer cell
lines. Cancer Lett. 291:200–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bao X, Cui J, Wu Y, et al: The roles of
endogenous reactive oxygen species and nitric oxide in
triptolide-induced apoptotic cell death in macrophages. J Mol Med
(Berl). 85:85–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lau AT, Wang Y and Chiu JF: Reactive
oxygen species: current knowledge and applications in cancer
research and therapeutic. J Cell Biochem. 104:657–667. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Engel RH and Evens AM: Oxidative stress
and apoptosis: a new treatment paradigm in cancer. Front Biosci.
11:300–312. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dias N and Bailly C: Drugs targeting
mitochondrial functions to control tumor cell growth. Biochem
Pharmacol. 70:1–12. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen G, Zhang X, Zhao M, et al: Celastrol
targets mitochondrial respiratory chain complex I to induce
reactive oxygen species-dependent cytotoxicity in tumor cells. BMC
Cancer. 11:1702011. View Article : Google Scholar
|
|
44
|
Mabuchi S, Ohmichi M, Nishio Y, et al:
Inhibition of NFkappaB increases the efficacy of cisplatin in in
vitro and in vivo ovarian cancer models. J Biol Chem.
279:23477–23485. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park B, Sung B, Yadav VR, Chaturvedi MM
and Aggarwal BB: Triptolide, histone acetyltransferase inhibitor,
suppresses growth and chemosensitizes leukemic cells through
inhibition of gene expression regulated by
TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway. Biochem Pharmacol.
82:1134–1144. 2011. View Article : Google Scholar
|
|
46
|
Wang J, Zhou JY, Zhang L and Wu GS:
Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in
ovarian cancer cells. Cell Cycle. 8:3191–3198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mansouri A, Zhang Q, Ridgway LD, Tian L
and Claret FX: Cisplatin resistance in an ovarian carcinoma is
associated with a defect in programmed cell death control through
XIAP regulation. Oncol Res. 13:399–404. 2003.PubMed/NCBI
|
|
48
|
Schreck R, Rieber P and Baeuerle PA:
Reactive oxygen intermediates as apparently widely used messengers
in the activation of the NF-kappa B transcription factor and HIV-1.
EMBO J. 10:2247–2258. 1991.PubMed/NCBI
|
|
49
|
Van Waes C: Nuclear factor-kappaB in
development, prevention, and therapy of cancer. Clin Cancer Res.
13:1076–1082. 2007.PubMed/NCBI
|
|
50
|
Korn SH, Wouters EF, Vos N and
Janssen-Heininger YM: Cytokine-induced activation of nuclear
factor-kappa B is inhibited by hydrogen peroxide through oxidative
inactivation of IkappaB kinase. J Biol Chem. 276:35693–35700. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kapahi P, Takahashi T, Natoli G, et al:
Inhibition of NF-kappa B activation by arsenite through reaction
with a critical cysteine in the activation loop of Ikappa B kinase.
J Biol Chem. 275:36062–36066. 2000. View Article : Google Scholar : PubMed/NCBI
|
